Carisbamate

Key facts

Active substance
Carisbamate
Therapeutic area
Neurology
Decision number
P/108/2009
PIP number
Carisbamate
Pharmaceutical form(s)
  • Film-coated tablet
  • Oral suspension
  • Intravenous formulation
Condition(s) / indication(s)
  • Infantile spasms (West Syndrome)
  • Lennox-Gastaut Syndrome
  • Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures
  • Neonatal seizures
  • Other paediatric epilepsy syndromes such as Dravet Syndrome, myoclonic astatic syndrome, epilepsy with continuous sharp-waves in sleep, idiopathic partial epilepsy, absence epilepsy
Route(s) of administration
  • Oral use
  • Intravenous use
Contact for public enquiries
Janssen Cilag International NV (Belgium)

E-mail: bbyl@its.jnj.com
Country: Belgium
Phone: +32 14607172
Fax: +3214606377
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

Topics

How useful was this page?

Add your rating